Clinical Trials Directory

Trials / Completed

CompletedNCT03618420

Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

CASPER Study: Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
50 (actual)
Sponsor
University of Colorado, Denver · Academic / Other
Sex
All
Age
12 Years – 21 Years
Healthy volunteers
Not accepted

Summary

Over 1.25 million Americans have type 1 diabetes (T1D), increasing risk for early death from cardiorenal disease. The strongest risk factor for cardiovascular disease (CVD) and mortality in T1D is diabetic kidney disease (DKD). Current treatments, such as control of hyperglycemia and hypertension, are beneficial, but only partially protect against DKD. Hyperfiltration is common in youth with T1D, and predicts progressive DKD. Hyperfiltration is also associated with early changes in intrarenal hemodynamic function, including increased renal plasma flow (RPF) and glomerular pressure. Intrarenal hemodynamic function is strongly influenced by the renin-angiotensin-aldosterone system (RAAS), which is also considered a key player in the pathogenesis of DKD. Preliminary data demonstrate differences in intrarenal hemodynamic function and RAAS activation in early and advanced DKD in T1D. However, the pathophysiology contributing to the differences observed in RAAS activation and intrarenal hemodynamic function in T1D are poorly defined Animal research demonstrates that arginine vasopressin (AVP) acts directly to modify intrarenal hemodynamic function, but also indirectly by activating RAAS. Preliminary data suggest that elevated copeptin, a marker of AVP, which predicts DKD in T1D adults, independently of other risk factors. However, no human studies to date have examined how copeptin relates to intrarenal hemodynamic function in early DKD in T1D. A better understanding of this relationship is critical to inform development of new therapies targeting the AVP system in T1D. Accordingly, in this study, the investigators propose to define the relationship between copeptin and intrarenal hemodynamics in early stages of DKD, by studying copeptin levels, renal plasma flow, and glomerular filtration in youth (n=50) aged 12-21 y with T1D duration \< 10 y.

Conditions

Interventions

TypeNameDescription
DRUGAminohippurate Sodium Inj 20%Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
DRUGIohexol Inj 300 mg/mLDiagnostic aid/agent used to measure glomerular filtration rate (GFR)

Timeline

Start date
2018-10-01
Primary completion
2019-10-19
Completion
2021-08-01
First posted
2018-08-07
Last updated
2022-04-20
Results posted
2021-08-31

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03618420. Inclusion in this directory is not an endorsement.